Reading LXEO? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track LXEO free→Reading LXEO? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track LXEO free→QuarterlyIQ Insights · LXEO
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Other Events. On June 15, 2026, Lexeo Therapeutics, Inc. (the "Company") issued a press release a nnouncing the regulatory updates to LX2006 for the treatment of Friedreich ataxia (FA) cardiomyopathy including the pivotal study design to support accelerated approval. As part of the pre ss release, the Company announced that it would be hosting a conference call and webcast at 8:00 a.m. ET on June 15, 2026 to discuss regulatory updates on LX2006 for the treatment of FA cardiomyopathy. The pres…
and Exhibit 99.1 hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “ Exchange Act ”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any of the Company’s filings under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as expressly set forth by specific reference in such a filing.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (d) Appointment of New Director On April 28, 2026 (the “ Appointment Date ”), Dr. Laura Sepp-Lorenzino was appointed to the board of directors (the “ Board ”) of Lexeo Therapeutics, Inc. (the “ Company ”). Dr. Sepp-Lorenzino will serve as a director with a term of office expiring at the Company’s 2028 Annual Meeting of Stockholders. As of the Appoi…
and Exhibit 99.1 hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “ Exchange Act ”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any of the Company’s filings under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as expressly set forth by specific reference in such a filing.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On January 30, 2026, Lexeo Therapeutics, Inc. (the “Company”) entered into a Transition and Consulting Agreement (the “Transition Agreement”) with Dr. Adler, effective February 1, 2026, pursuant to which Dr. Adler stepped down from his role of Head of Research and will continue to provide certain advisory services to the Company until the earlier o…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Appointment of Chief Operating Officer On January 27, 2026, Lexeo Therapeutics, Inc. (the “Company”) announced that the Board of Directors of the Company (the “Board”) appointed Jose Manuel Otero, Ph.D., the Company’s current Chief Technical Officer, to serve as Chief Operating Officer of the Company, effective as of January 2, 2026. For Dr. Otero’…
Other Events. On January 12, 2026, Lexeo Therapeutics, Inc. (the “Company”) issued a press release announcing positive interim Phase 1/2 clinical data of LX2020 for the treatment of PKP2-associated arrhythmogenic cardiomyopathy (“PKP2-ACM”). As part of the press release, the Company announced that it would be hosting a conference call and webcast at 8:00 a.m. ET on January 12, 2026 to discuss the interim Phase 1/2 clinical data of LX2020 for the treatment of PKP2-ACM. The press release is att…
and Exhibit 99.1 hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any of the Company’s filings under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as expressly set forth by specific reference in such a filing.
Entry into a Material Definitive Agreement. Underwriting Agreement On October 16, 2025, Lexeo Therapeutics, Inc. (the “ Company ”) entered into an underwriting agreement (the “ Underwriting Agreement ”) with Leerink Partners LLC, as representative (the “ Representative ”) of the several underwriters named therein (collectively, the “ Underwriters ”), relating to the issuance and sale in a public offering (the “ Public Offering ”) of 15,625,000 shares (the “ Firm Shares ”) of the Company’s com…
of this Current Report on Form 8-K. The Company will sell the Pre-Funded Warrants to an “accredited investor,” as that term is defined in the Securities Act, in reliance on the exemption from registration afforded by Section 4(a)(2) of the Securities Act and corresponding provisions of state securities or “blue sky” laws. The Purchaser represented that it is acquiring the Pre-Funded Warrants for investment only and not with a view towards the resale or distribution thereof in violation of the…
Other Events Clinical Update – LX2006 In October 2025, the Company announced progress in regulatory interactions with the FDA on the LX2006 program. In response to questions from the Company regarding the possibility of a faster path to a Biologics License Application, or BLA, the FDA has indicated openness to a BLA submission for accelerated approval that includes clinical data from the Company’s ongoing Phase I/II studies of LX2006 pooled with new clinical data to be generated in the planne…
Results of Operations and Financial Condition. On October 16, 2025, the Company disclosed in a preliminary prospectus supplement relating to the Public Offering that, as of September 30, 2025, the Company estimates that it had $122.8 million of cash, cash equivalents and investments. The preliminary financial information has been prepared by, and is the responsibility of, the Company’s management and has been prepared in good faith on a consistent basis with prior periods. The Company’s indep…
and Exhibit 99.1 hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any of the Company’s filings under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as expressly set forth by specific reference in such a filing.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. CFO Transition On August 14, 2025, Lexeo Therapeutics, Inc. (the “Company”) announced that the Board of Directors of the Company (the “Board”) appointed Louis Tamayo to serve as the Company’s Chief Financial Officer effective August 15, 2025 (the “Effective Date”). In connection with Mr. Tamayo’s appointment as Chief Financial Officer, Mr. Tamayo w…
by reference. The information in this Item 7.01, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act, except as expressly set forth by specific reference in such filing. Forward Looking Statements This report contains certain forward-looking statements regarding the business of the Compa…
Entry into a Material Definitive Agreement. Securities Purchase Agreement On May 27, 2025, Lexeo Therapeutics, Inc. (the “ Company ”) entered into a Securities Purchase Agreement (the “ Purchase Agreement ”) for a private placement (the “ Private Placement ”) with certain qualified institutional buyers and institutional accredited investors (each, a “ Purchaser ” and collectively, the “ Purchasers ”). Pursuant to the Purchase Agreement, the Company agreed to sell to the Purchasers an aggregat…
of this Current Report on Form 8-K. The Company will sell the Securities to “accredited investors,” as that term is defined in the Securities Act, in reliance on the exemption from registration afforded by Section 4(a)(2) of the Securities Act and corresponding provisions of state securities or “blue sky” laws. The Purchasers represented that they are acquiring the Securities for investment only and not with a view towards the resale or distribution thereof in violation of the Securities Act.…
and Exhibit 99.1 hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “ Exchange Act ”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any of the Company’s filings under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as expressly set forth by specific reference in such a filing.
and Exhibit 99.1 hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “ Exchange Act ”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any of the Company’s filings under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as expressly set forth by specific reference in such a filing.
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.